The stock of TESARO Inc (NASDAQ:TSRO) hit a new 52-week high and has $205.30 target or 53.00% above today’s $134.18 share price. The 6 months bullish chart indicates low risk for the $6.95 billion company. The 1-year high was reported on Nov, 9 by Barchart.com. If the $205.30 price target is reached, the company will be worth $3.68B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 734,903 shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 156.12% since April 7, 2016 and is uptrending. It has outperformed by 151.33% the S&P500.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 13 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 85% are positive. Tesaro Inc has been the topic of 23 analyst reports since August 24, 2015 according to StockzIntelligence Inc. FBR Capital maintained it with “Outperform” rating and $133 target price in Friday, November 4 report. Wedbush initiated the shares of TSRO in a report on Thursday, January 21 with “Outperform” rating. Leerink Swann maintained it with “Outperform” rating and $115 target price in Monday, October 10 report. Lake Street maintained it with “Buy” rating and $150 target price in Monday, November 7 report. The rating was initiated by Bank of America with “Neutral” on Tuesday, August 30. As per Monday, August 24, the company rating was initiated by Leerink Swann. The stock of TESARO Inc (NASDAQ:TSRO) earned “Outperform” rating by Robert W. Baird on Tuesday, July 19. On Wednesday, June 29 the stock rating was maintained by FBR Capital with “Outperform”. On Monday, October 10 the stock rating was upgraded by Bank of America to “Buy”. The stock of TESARO Inc (NASDAQ:TSRO) earned “Buy” rating by Mizuho on Friday, August 5.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.55 in Q2 2016. Its up 0.32, from 1.23 in 2016Q1. The ratio increased, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
Cornerstone Cap Management accumulated 0% or 700 shares. Eam Invsts Limited Company, a California-based fund reported 33,741 shares. Morgan Stanley owns 69,534 shares or 0% of their US portfolio. Schwab Charles Investment Mngmt has invested 0.01% of its portfolio in TESARO Inc (NASDAQ:TSRO). Fred Alger Mgmt reported 103,777 shares or 0.05% of all its holdings. Geode Capital Mgmt Limited holds 237,044 shares or 0.01% of its portfolio. Vanguard Group Incorporated owns 2.22M shares or 0.01% of their US portfolio. Putnam Ltd Liability Com last reported 0.17% of its portfolio in the stock. Moreover, Oracle Mngmt has 13.05% invested in TESARO Inc (NASDAQ:TSRO) for 666,956 shares. The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in TESARO Inc (NASDAQ:TSRO). Sei Invests has 68 shares for 0% of their US portfolio. Whittier Company Of Nevada accumulated 400 shares or 0% of the stock. Moreover, Hatteras Funds Ltd Llc has 7.19% invested in TESARO Inc (NASDAQ:TSRO) for 15,310 shares. Turner Invests Ltd Partnership holds 0.26% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 9,690 shares. Whittier Tru Company holds 10,839 shares or 0.04% of its portfolio.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 6 selling transactions for $4.43 million net activity. $2.51 million worth of TESARO Inc (NASDAQ:TSRO) was sold by Hanke Jeffrey H.. The insider Huber Martin H. Jr. sold 327 shares worth $39,662. English Edward C also sold $285,274 worth of TESARO Inc (NASDAQ:TSRO) on Friday, June 10.
More news for TESARO Inc (NASDAQ:TSRO) were recently published by: Fool.com, which released: “Why Tesaro, Inc. Is Skyrocketing 20% Today” on October 10, 2016. Investorplace.com‘s article titled: “Tesaro Inc (TSRO) Soars on Trial Data, Analyst Upgrades” and published on October 10, 2016 is yet another important article.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.